Pluvicto under the microscope: how does it perform in real life?
NCT ID NCT06514521
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study follows 278 men with advanced prostate cancer who are already receiving Pluvicto as part of their routine care in South Korea. Researchers will monitor side effects and how well the drug controls the cancer over time. No new treatment is given—this is purely an observation to see how Pluvicto works in real-world settings.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Lutetium (177Lu) vipivotide tetraxetan (Pluvicto)
What this could lead to
If successful, this study will confirm how safe and effective Pluvicto is in everyday clinical practice, supporting its continued use for advanced prostate cancer.
What could go wrong
This is an observational study, not a controlled trial, so results may be influenced by patient selection and real-world variability. It does not test a new treatment or compare with alternatives.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Locations
-
Novartis Investigative Site
RECRUITINGSeongnam-si, Gyeonggi-do, 13620, South Korea
-
Novartis Investigative Site
RECRUITINGSuwon, Gyeonggi-do, 442-723, South Korea
-
Novartis Investigative Site
RECRUITINGBusan, Korea, 46033, South Korea
-
Novartis Investigative Site
RECRUITINGGyeonggi-do, Korea, 10408, South Korea
-
Novartis Investigative Site
RECRUITINGSeoul, Seoul, 03374, South Korea
-
Novartis Investigative Site
RECRUITINGSeoul, Seoul, 06351, South Korea
-
Novartis Investigative Site
RECRUITINGSeoul, 01812, South Korea
-
Novartis Investigative Site
RECRUITINGSeoul, 03722, South Korea
-
Novartis Investigative Site
RECRUITINGSeoul, 05505, South Korea
-
Novartis Investigative Site
RECRUITINGSeoul, 06591, South Korea
-
Novartis Investigative Site
RECRUITINGSeoul, 110-744, South Korea